Actinium Pharmaceuticals (ATNM) Current Deferred Revenue (2021 - 2023)
Actinium Pharmaceuticals (ATNM) posted quarterly Current Deferred Revenue of $8.2 million for Q4 2023, down 76.52% year-over-year from $35.0 million in Q4 2022, and down 76.52% quarter-over-quarter from $35.0 million in Q3 2023.
Actinium Pharmaceuticals (ATNM) Current Deferred Revenue (2021 - 2023) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Current Deferred Revenue for 3 consecutive years, with $8.2 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Current Deferred Revenue fell 76.52% year-over-year to $8.2 million; the TTM figure through Dec 2023 stood at $8.2 million (down 76.52% YoY), while the FY2023 annual figure was $8.2 million, down 76.52% from the prior year.
- Current Deferred Revenue eased to $8.2 million in Q4 2023 per ATNM's latest filing, from $35.0 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $35.0 million in Q3 2022 and bottomed at $100000.0 in Q1 2022.
- Historically, Current Deferred Revenue has averaged $16.6 million across 3 years, with a median of $8.2 million in 2023.
- On a YoY basis, Current Deferred Revenue climbed as much as 34900.0% in 2023 and fell as far as 76.52% in 2023.
- Actinium Pharmaceuticals' Current Deferred Revenue stood at $1.0 million in 2021, then soared by 3400.0% to $35.0 million in 2022, then sank by 76.52% to $8.2 million in 2023.
- Business Quant data shows ATNM's Current Deferred Revenue at $8.2 million in Q4 2023, $35.0 million in Q3 2023, and $100000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 8.22 Mn |
| Sep 30, 2023 | 35.00 Mn |
| Jun 30, 2023 | 100,000.00 |
| Mar 31, 2023 | 35.00 Mn |
| Dec 31, 2022 | 35.00 Mn |
| Sep 30, 2022 | 35.00 Mn |
| Jun 30, 2022 | 200,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Dec 31, 2021 | 1.00 Mn |